Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-R-ICE versus R-ICE for relapsed or refractory diffuse large B-cell lymphoma
ISRCTN13438605Phase 3Completed
- Sponsor
- GWT-TUD
- Start
- Apr 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma, sponsored by GWT-TUD. Started Apr 2021; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on ISRCTN13438605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13438605.